The expansion of COVID-19 in the world has not ended yet, and the situation in Japan is still unpredictable. Under these circumstances, the development of SARS-CoV-2 treatments such as vaccines and medicines is still underway. Since April of this year, we have been conducting research on the drug screening for SARS-CoV-2 using the supercomputer "Fugaku". In my talk, I would like to talk about the impact of the supercomputer "Fugaku" on drug discovery, by exemplifying the in silico drug screening for SARS-CoV-2.